The United States Patent and Trademark Office recently issued a notice of allowance for US patent application number 15/568,655 covering Technophage’s TZ-113 project.

TZ-113 is a repurposing project for Parkinson’s patients targeting levodopa induced diskynesia during OFF periods. US15/568,655 is the most recent addition to Technophage’s list of allowed patents.

Technophage patent portfolio is now composed of 60 granted patents (including national validations in Europe) and 39 patent applications covering a variety of territories.